Leukemia CancerConnect
Treatment of Adult Acute Lymphoblastic Leukemia
Cancer Connect - Treatment of Adult Acute Lymphoblastic Leukemia
STAMP inhibitor Scemblix (ssciminib, ABL001) for CML
Scemblix superior responses compared to Bosulif for treatment of chronic myeloid leukemia - active in T315I mutations
Two Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
Research suggests some patients with CML can safely discontinue TKI therapy - NCCN guidelines published.
Leukemia Cancer Connect is a unique resource that brings patients, caregivers, advocates and experts together in a single community where individuals benefit from a blend of expert-authored news and educational programming alongside a robust social network, providing insight into symptoms, diagnosis, treatment, and the support of other individuals being treated at some of the best cancer centers. Leukemia Cancer Connect offers users expert authored clinically-reviewed information and the perspective of their peers in a safe, objective space, helping to ensure they become empowered in their healthcare journey.
Leukemia Cancer Connect is a unique resource that brings patients, caregivers, advocates and experts together in a single community where individuals benefit from a blend of expert-authored news and educational programming alongside a robust social network, providing insight into symptoms, diagnosis, treatment, and the support of other individuals being treated at some of the best cancer centers. Leukemia Cancer Connect offers users expert authored clinically-reviewed information and the perspective of their peers in a safe, objective space, helping to ensure they become empowered in their healthcare journey.
Leukemia Overviews
Treatment of Adult Acute Lymphoblastic Leukemia
Cancer Connect - Treatment of Adult Acute Lymphoblastic Leukemia
Understanding TKI Therapy and Drug Resistance in Chronic Myelogenous Leukemia
Drug resistance can occur when CML no longer responds to a TKI and there are a number of possible causes
Acute Myeloid Leukemia: Overview and Treatment
Management of Acute Myeloid Leukemia: Induction, Consolidation, Precision Medicines and Stem Cell Transplantation.
Acute Myeloid Leukemia Treatment Options Expand With Recent FDA Approvals
FDA Approves Venclexta, Daurismo, and Xospata Precision Cancer Medicines for Treatment of Acute Myeloid Leukemia
Acute Leukemia
Blincyto Prolongs Survival in Acute Lymphoblastic Leukemia (ALL)
Studies continue to demonstrate that incorporation of Blincyto into ALL treatment improves patient outcomes.
Vidaza® May Provide Alternative Treatment for Elderly Patients with AML
Vidaza® May Provide Alternative Treatment for Elderly Patients with AML.
Venclexta® for Acute Myeloid Leukemia
Venclexta® expands treatment options for AML - ASCO 2020 update in elderly AML patients confirms benefit.
FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia
FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia
Chronic Leukemia
STAMP inhibitor Scemblix (ssciminib, ABL001) for CML
Scemblix superior responses compared to Bosulif for treatment of chronic myeloid leukemia - active in T315I mutations
Two Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
Research suggests some patients with CML can safely discontinue TKI therapy - NCCN guidelines published.
Iclusig (ponatinib) Treatment of Chronic Myelod Leukemia
Iclusig (ponatinib) is an effective treatment for CML.
Understanding TKI Therapy and Drug Resistance in Chronic Myelogenous Leukemia
Drug resistance can occur when CML no longer responds to a TKI and there are a number of possible causes
Leukemia Survivorship
COVID-19 Vaccination in Patients with Blood Cancers
Studies of COVID-19 vaccine effectiveness in myeloma and lymphoma available - vaccine relatively ineffective.
Ask the Expert: Fertility after Cancer Treatment
Dr Leslie Diller M.D. of Dana Farber Cancer Center discusses cancer and fertility.
Cancer and Fertility Options for Women
Overview of fertility options for women diagnosed with cancer from Memorial Sloan Kettering's Cancer & Fertility Program